Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes

NCT01435980 on ClinicalTrials.gov · last registry update 2015-03-27

60 participants. Its estimated completion date, January 2016, has passed with no update to the record. Primary outcome, as filed: Clinical events. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Wu Qinan
Sponsor type: Other
Enrollment: 60
Started: 2008-02
Primary completion: 2016-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Clinical events

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.